budesonide/formoterol / Generic mfg. - LARVOL DELTA

TWO CASES OF ASTHMA INDUCED BY SMOKE FROM BURNING RICE STRAWS AND RICE HUSKS (PubMed, Arerugi) - "The peripheral eosinophil counts and fractional exhaled nitric oxide levels were not elevated, indicating no association with eosinophilic airway inflammation. Symbicort maintenance and reliever therapy was effective in reducing the systemic steroid dose in both cases."

Journal • Asthma • Cough • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Budesonide/Glycopyrrolate/Formoterol Fumarate Effects on Lung Function and Exacerbations by Baseline Exacerbation History in Inadequately Controlled Asthma: Post Hoc Analyses of KALOS and LOGOS Studies (AAAAI 2026) - "Rationale KALOS and LOGOS compared budesonide/glycopyrrolate/formoterol fumarate (BGF) with budesonide/formoterol fumarate (BFF) or Symbicort® (BUD/FORM) administered via metered-dose inhaler...Similar findings (all p≤0.006) were observed for change from baseline (mL) for morning pre-dose trough FEV1 (KALOS: none [103 (51, 155)], ≥1 [53 (15, 90)]; LOGOS: none [85 (41, 129)], ≥1 [97 (51, 143)]). Annualized pooled exacerbation risk (rate ratio Conclusions BGF 36 improved lung function and reduced exacerbation risk versus BUD/FORM, with similar treatment effects regardless of whether participants had exacerbations in the 12 months prior to enrollment."

Retrospective data • Asthma • Immunology • Respiratory Diseases

ARRIVAL: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (clinicaltrials.gov) - P3 | N=296 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Safety Assessment of Budesonide/Formoterol: Real-World Pharmacovigilance Analysis Using the FAERS, JADER, and CVAR Databases. (PubMed, Clin Ther) - "This multi-database analysis highlights the need for continuous pharmacovigilance for budesonide/formoterol. The identification of novel ADE signals emphasizes the importance of vigilant monitoring, especially during early treatment, to enhance safety and therapeutic outcomes."

Adverse events • Journal • Real-world evidence • Alopecia • Alzheimer's Disease • Asthma • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Cough • Dysphonia • Endocrine Disorders • Hepatology • Immunology • Infectious Disease • Liver Failure • Myocardial Infarction • Pneumonia • Pulmonary Disease • Respiratory Diseases

Dongtian Changchun ointment for moderate-to-severe chronic obstructive pulmonary disease: a multicenter, prospective, open-label, randomized controlled trial. (PubMed, J Tradit Chin Med) - "DTCO significantly reduced the frequency and duration of AECOPD in patients with moderate-to-severe COPD, and demonstrated satisfactory safety."

Clinical • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Clinical effectiveness of anti-inflammatory reliever therapies (AIR) for exacerbation prevention: a non-inferiority study (BTS WM 2025) - "We conducted a non-inferiority study (pre-specified 20% non-inferiority margin; IRR 1.20) for exacerbation prevention of BDP-F (Fostair) AIR compared with BUD-F (Symbicort) AIR. Incidence of CVD events post-initiation of AIR was similar for both groups: IRR=1.04 for BDP-F vs BUD-F [0.46,2.34]). BDP-F AIR is non-inferior to BUD-F AIR for exacerbation prevention, results in significantly lower OCS use, and has comparable outcomes for acute cardiovascular events."

Clinical • Head-to-Head • Asthma • Cardiovascular • Immunology • Respiratory Diseases

Budesonide/glycopyrronium/formoterol fumarate dihydrate triple therapy for inadequately-controlled asthma: KALOS and LOGOS study results (BTS WM 2025) - "KALOS and LOGOS, two Phase 3, double-blind, double-dummy randomised studies, compared fixed-dose triple combination budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) with budesonide/formoterol fumarate dihydrate via metered-dose inhaler (MDI; BFF) and via pressurised MDI ([Symbicort ® ] BUD/FORM)...BGF 320/28.8/10 μg is superior to dual ICS/LABA in adults and adolescents with asthma inadequately-controlled by ICS/LABA. View this table: View inline View popup Download powerpoint Abstract P297 Table 1 Summary of primary and secondary efficacy endpoint results (European regulatory approach)"

Asthma • Immunology • Respiratory Diseases

START CARE: STep-wise Anti-inflammatory Reliever Therapy Children’s Asthma REsearchn: A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist maintenance and/or reliever therapy versus standard maintenance with separate reliever therapy in children with mild, moderate and severe asthma. (ANZCTR) - P3 | N=400 | Active, not recruiting | Sponsor: Medical Research Institute of New Zealand | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

LUNG FUNCTION BENEFITS OF BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE TRIPLE THERAPY FOR THE TREATMENT OF INADEQUATELY CONTROLLED ASTHMA: KALOS AND LOGOS STUDY RESULTS (CHEST 2025) - "KALOS and LOGOS, two Phase III, double-blind, double-dummy, randomized studies, compared fixed-dose triple combination budesonide/glycopyrrolate/ formoterol fumarate via pressurized metered dose inhaler (pMDI) using Aerosphere co-suspension delivery technology (BGF) with budesonide/formoterol fumarate via pMDI using Aerosphere co-suspension delivery technology (BFF) or as Symbicort pMDI (BUD/FORM), which use slightly different formoterol fumarate doses (BFF, 9.6 μg; BUD/FORM, 9 μg)... BGF 36 is superior to dual ICS/LABA therapy with BUD/FORM on lung function and severe exacerbations adults and adolescents with asthma inadequately controlled by ICS/LABA. CLINICAL IMPLICATIONS: These findings suggest BGF 36 is a treatment option with meaningful effects in people with asthma inadequately controlled with ICS/LABA, including those without an exacerbation history in the previous year."

Late-breaking abstract • Asthma • Immunology • Respiratory Diseases

SPONTANEOUS LUNG HERNIATION: A RARE CASE COMPLICATED BY RIB FRACTURE (CHEST 2025) - "His symptoms persisted despite the use of albuterol and Symbicort... Spontaneous lung herniation is a rare condition that requires a high index of suspicion, particularly in patients with chronic lung diseases and persistent cough. Early recognition and appropriate intervention are critical to prevent complications. This case underscores the importance of considering spontaneous lung herniation in the differential diagnosis patients presenting with chest pain and respiratory distress, even in the absence of trauma."

Clinical • Asthma • Chronic Cough • Chronic Obstructive Pulmonary Disease • Cough • Gastroenterology • Immunology • Musculoskeletal Diseases • Orthopedics • Pulmonary Disease • Respiratory Diseases

REFRACTORY HYPERKALEMIA WITH STATUS ASTHMATICUS (CHEST 2025) - "CASE PRESENTATION: A 31-year-old-man with severe persistent asthma on Symbicort and albuterol presented to the emergency department with shortness of breath...Shortly after admission to the Intensive Care Unit, the patient developed an acute kidney injury (serum creatinine of 1.76) and hyperkalemia (6.1) refractory to medication intervention (including continuous albuterol, IV insulin with dextrose, sodium zirconium cyclosilicate) for which nephrology was consulted... The patient in this case most likely had hyperkalemia due to ATN which was exacerbated by elevated CK, drug use, severe respiratory acidosis, and possibly increased alpha adrenergic activity in the setting of albuterol. The mild degree of this patient's acute renal failure alone cannot explain his level of hyperkalemia."

Acute Kidney Injury • Asthma • Cardiovascular • Hypertension • Hypotension • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Respiratory Diseases

Chlamydia Pneumoniae in a Case of Treatment-Resistant Asthma (AAP-NCE 2025) - "The patient was treated with a 5-day course of Azithromycin, oral prednisone and twice daily low dose Symbicort with some improvement in symptoms, which then fully resolved 1 week after escalation to higher dose Symbicort treatment. 8 months prior, he experienced similar respiratory symptoms that failed to fully respond to oral corticosteroids, albuterol, and Amoxicillin, but eventually improved after Azithromycin. PCR testing for Chlamydia pneumoniae should be considered in patients who present with acute asthma exacerbations that do not respond to initial therapy with oral corticosteroids."

Clinical • Asthma • Cough • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases

Maintenance and reliever therapy (MART) in children less than 12 Years: A single-centre retrospective study (ERS 2025) - " We retrospectively reviewed electronic records of children <12 years initiated on Symbicort pMDI 100/3 (budesonide + formoterol) as MART at a tertiary centre, due to poorly controlled asthma... In children <12 years with asthma uncontrolled on first-line therapies, pMDI MART may reduce oral steroid requirements and exacerbation rates. Moreover, MART appears to be a safe therapy with no early impact on growth. Prospective data collection is ongoing in this patient cohort to report data up to 12months post MART initiation."

Retrospective data • Asthma • Immunology • Pediatrics • Respiratory Diseases

Extrafine beclometasone/formoterol is non-inferior to budesonide/formoterol as maintenance and reliever therapy (MART) for adult asthma patients and reduces the total carbon footprint of all inhaler-related greenhouse gas (GHG) emissions. (ERS 2025) - "To investigate non-inferiority of Fostair MART (BDP/FF-MART) compared to Symbicort MART (BUD/FF-MART) for exacerbation prevention and asthma control, and the carbon footprint of inhalers after initiation of BDP/FF-MART. As-needed SABA accounted for 34-54% of this reduction. BDP/FF-MART was non-inferior to BUD/FF-MART for severe exacerbations and asthma control and reduced the total carbon footprint of all inhaler-related GHG emissions."

Clinical • Asthma • Immunology • Respiratory Diseases

A SPARKLING SURPRISE: THE RETROCARDIAC MASS THAT SPARKLED WITH CHARCOT-LEYDEN CRYSTALS (MTS 2025) - "CasePresentation A 40-year-old female with background allergic bronchial asthma, well-controlled with Symbicort Turbohaler with rhinosinusitis presented with a 3-day history of fever, cough, and left shoulder pain...The patient was treated with six weeks of Amoxycillin-Clavulanic Acid...Conclusion This case highlights the histopathological manifestation of Charcot-Leyden Crystal in an asthmatic airway. Aside from that, encountering a mass-like thoracic infective lesion that mimics malignancy is quite intriguing."

Asthma • Cough • Immunology • Infectious Disease • Musculoskeletal Pain • Otorhinolaryngology • Respiratory Diseases • Sinusitis • Tuberculosis • CRP

Pharmacoeconomic Analysis of Medicines Used for Bronchial Asthma in Children in Kazakhstan. (PubMed, J Mother Child) - "This study's results indicate that the most cost-effective treatment regimen is in the age groups of 6-8 years. However, the calculation of drug dosages directly depends on the patient's age and the severity of the disease. Further actions in scientific works should be directed to conducting empirical, statistical studies in the field of pharmacoeconomics of bronchial asthma among children from the standpoint of the state."

HEOR • Journal • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Provider Perceptions of Inhaler Device Switching Following a Department of Veterans Affairs National Formulary Change (ATS 2025) - "In July 2021, the Veterans Health Administration (VA) changed its national formulary from budesonide-formoterol (Symbicort HFA), a metered-dose inhaler, to fluticasone-salmeterol (Wixela Inhub), a dry-powder inhaler. Limitations include both recall and non-response bias. Additional research is needed to understand processes used to inform patients and clinicians around formulary changes, which are increasingly common as pharmacy benefits managers seek to cut costs, and to identify opportunities for improved patient communication."

Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Case of Constrictive Bronchiolitis Secondary to Vaping in Active Duty Servicemember (ATS 2025) - "Intraoperative cultures were notable for presence of penicillium for which patient was seen by Infectious Disease and treated with a prolonged course of itraconazole. For patient's diffuse lung disease smoking cessation was achieved, and he was initiated on azithromycin and montelukast therapy in addition to inhaler therapy with Symbicort...CB is a rare entity however should be considered in those presenting with respiratory symptoms and reports of electronic cigarette use."

Clinical • Gastrointestinal Disorder • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tobacco Cessation

Insights From Case Series on Asthma-COPD Overlap (ACO) as an Independent Entity (ATS 2025) - "Her COPD was initially managed with standard bronchodilator therapy, including Trelegy and Singulair...Treatment included Symbicort and Spiriva, with further allergist referral resulting in targeted allergen immunotherapy...Biologic therapies like benralizumab and dupilumab effectively control eosinophilic inflammation and improve lung function, emphasizing the importance of individualized treatment...These cases highlight the need for a comprehensive, patient-centered approach in ACO care, integrating biologic and allergen-targeted therapies to enhance quality of life. Continued research is essential to understand ACO's pathophysiology and optimize treatments."

Clinical • Allergic Rhinitis • Asthma • Chronic Cough • Chronic Obstructive Pulmonary Disease • Cough • Immunology • Infectious Disease • Inflammation • Pneumonia • Respiratory Diseases

From Lymphoma to Histoplasmosis: A Diagnostic Journey in a Marathon Runner (ATS 2025) - "Initially diagnosed with bronchitis by her primary care physician, she was treated with Two courses of Augmentin and prednisone with no improvement in symptoms. Pulmonary function tests indicated asthma, and she was prescribed Symbicort, but her condition continued to worsen. A chest X-ray, taken 10 days before admission, revealed right lower lobe pneumonia, and she was started on doxycycline... Our case highlights the difficulty in diagnosing infections like Histoplasma which can mimic malignancy and emphasizes the need for high degree of suspicion and thorough diagnostic testing required when patient fails to improve with appropriate treatment."

Asthma • Fatigue • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Small Lymphocytic Lymphoma • CD5

Clinical Outcomes After Switching From Metered-Dose Inhaler Budesonide-Formoterol to Dry-Powder Inhaler Fluticasone-Salmeterol in a Nationwide Veteran Cohort (ATS 2025) - "In July 2021, the Veterans Health Administration (VA) transitioned its preferred inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) controller from budesonide-formoterol MDI (Symbicort) to fluticasone-salmeterol DPI (Wixela Inhub). In this national cohort of veterans who switched from an MDI to a DPI controller during a national formulary transition, the DPI, Wixela Inhub, was associated with decreased use of rescue albuterol but increased use of prednisone and increases in all-cause and respiratory-related ED visits and hospitalizations."

Clinical • Clinical data • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Breath of Change: Evaluating Inhaler Use and Compliance in Hospital Transitions (ATS 2025) - "Our tertiary academic center, Rush University Medical Center (RUMC), has two long-acting inhalers on formulary, Spiriva (tiotropium) and Symbicort (budesonide-formoterol), which are used during admission in place of any other prior to admission inhalers... Many patients who were discharged on a new inhaler reported confusion regarding their inhaler regimen at post-hospitalization follow-up per physician documentation. On further review of this patient cohort, only 1 patient had a clinical indication for an inhaler change during hospitalization. This indicates that nonmedical switching can lead to patient confusion and ultimately medication non-compliance."

Clinical • Compliance • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Understanding How Formulary Pricing Models Shape Medication Accessibility and Financial Burden for Aging Populations (ISPOR 2025) - "Alzheimer’s treatments like galantamine and rivastigmine were often in higher tiers, raising out-of-pocket costs. COPD medications, including Symbicort and Trelegy Ellipta, despite preferred tier placement, posed financial challenges. Rheumatoid arthritis drugs, particularly Humira in Tier 5, imposed heavy costs. Similarly, ischemic heart disease and type 2 diabetes medications like Eliquis and Steglatro often appeared in higher tiers, worsening adherence issues... Older patients in the U.S., particularly those dealing with chronic illnesses, still encounter significant financial pressure due to increasing prescription prices. Although initiatives such as the Inflation Reduction Act provide some assistance, the strain persists, leading to low compliance and adverse health results. The results highlight the urgent necessity for strong policies to improve price transparency, increase access to affordable generics, and stop the unjust classification of generics in higher..."

Clinical • Pricing • Alzheimer's Disease • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Coronary Artery Disease • Diabetes • Heart Failure • Immunology • Inflammatory Arthritis • Metabolic Disorders • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Type 2 Diabetes Mellitus

DELAYED PRESENTATION OF HORNER'S SYNDROME AFTER AN INTERSCALENE BLOCK (ASRA-SPRING 2025) - "Patient’s past medical history is significant for mild asthma for which she takes symbicort daily and albuterol as needed, she also has anxiety for which she takes no medications...Consideration should be given to rule out other causes of the symptoms before assuming it is from the block. However, one should not rule out a delayed onset of symptoms and prolonged duration of symptoms after a one shot Interscalene block, as in this case."

Anesthesia • Asthma • Cardiovascular • Immunology • Infectious Disease • Musculoskeletal Pain • Ophthalmology • Otorhinolaryngology • Pain • Psychiatry • Respiratory Diseases

Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol) Using Physiologically-Based Pharmacokinetic Model. (PubMed, Clin Pharmacol Ther) - "In addition, the clinical study could also include a lower flow rate (30-50 L/min) patient population to further evaluate the advantages of the modified formulation CXG87. This is the first study to predict CXG87 local exposure by a verified PBPK model."

Journal • PK/PD data • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases